Amyloid-β — a reflection of risk or a preclinical marker?

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In a recent study, individuals with brain amyloid-β accumulation but no cognitive impairment were classified as being at risk of Alzheimer disease, yet amyloid-β is widely considered to be a pathological biomarker of Alzheimer disease rather than a risk factor — it cannot be both.

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalNature Reviews Neurology
DOIs
StateAccepted/In press - Apr 30 2018

Fingerprint

Amyloid
Alzheimer Disease
Biomarkers
Brain
Cognitive Dysfunction

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

@article{b41cdee9640f457b8aa8ab9acb698365,
title = "Amyloid-β — a reflection of risk or a preclinical marker?",
abstract = "In a recent study, individuals with brain amyloid-β accumulation but no cognitive impairment were classified as being at risk of Alzheimer disease, yet amyloid-β is widely considered to be a pathological biomarker of Alzheimer disease rather than a risk factor — it cannot be both.",
author = "Jack, {Clifford R Jr.} and Vemuri, {Prashanthi D}",
year = "2018",
month = "4",
day = "30",
doi = "10.1038/s41582-018-0008-9",
language = "English (US)",
pages = "1--2",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Amyloid-β — a reflection of risk or a preclinical marker?

AU - Jack, Clifford R Jr.

AU - Vemuri, Prashanthi D

PY - 2018/4/30

Y1 - 2018/4/30

N2 - In a recent study, individuals with brain amyloid-β accumulation but no cognitive impairment were classified as being at risk of Alzheimer disease, yet amyloid-β is widely considered to be a pathological biomarker of Alzheimer disease rather than a risk factor — it cannot be both.

AB - In a recent study, individuals with brain amyloid-β accumulation but no cognitive impairment were classified as being at risk of Alzheimer disease, yet amyloid-β is widely considered to be a pathological biomarker of Alzheimer disease rather than a risk factor — it cannot be both.

UR - http://www.scopus.com/inward/record.url?scp=85046085220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046085220&partnerID=8YFLogxK

U2 - 10.1038/s41582-018-0008-9

DO - 10.1038/s41582-018-0008-9

M3 - Article

SP - 1

EP - 2

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

ER -